Relationship between Plasma Aldosterone Concentration and Soluble Cellular Adhesion Molecules in Patients Referred to Coronary Angiography

Abstract

Objective:

Evidence is emerging that aldosterone contributes to the development and progression of atherosclerosis and cardiovascular disease. Little is known, however, regarding an association between circulating aldosterone levels and soluble cellular adhesion molecules in humans.

Methods:

We investigated the relationship between plasma aldosterone concentration (PAC) and soluble cellular adhesion molecules in a large cohort of patients referred to coronary angiography. After exclusion of patients with ongoing mineralocorticoid receptor blocker use, oral contraceptive or hormone replacement therapy, 1 733 patients (mean age: 62.5±10.8 years; 26.4%% women; mean PAC: 101.5±93.5 pg/mL) remained eligible for analyses.

Results:

Pearson correlation analysis as well as age and gender adjusted partial correlation analysis revealed a positive association between PAC and soluble (s) E-, L- and P-selectin levels but not with sICAM-1 and sVCAM-1, respectively. In multivariate adjusted analyses of covariance (ANCOVA) sE- (p=0.026), sL- (p=0.049) and sP-selectin (p<0.001) levels increased steadily from the first (reference) to the third gender-specific tertile of PAC. No significant variation across PAC tertiles was found for sICAM-1 (p=0.767) and sVCAM1 (p=0.425) levels, respectively. Finally, multivariate regression analyses revealed circulating aldosterone as an important predictor for soluble selectin levels.

Conclusion:

Our findings in a large cohort of patients indicate that upregulation of selectins might represent a novel mechanism of aldosterone mediated development and progression of atherosclerosis. In view of aldosterone as a novel cardiovascular risk factor independent of angiotensin II, our findings warrant further interventional studies which should evaluate anti-atherosclerotic effects of aldosterone blocking treatment strategies in humans.

Key words

plasma aldosterone - soluble cellular adhesion molecules

^*

^* These authors contributed equally to this work.

• References

• 1 Tomaschitz A, Pilz S, Ritz E et al. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2010; 6: 83-93
• 2 Rossi GP, Di Bello V, Ganzaroli C et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-27
• 3 Sechi LA, Novello M, Lapenna R et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645
• 4 Mulatero P, Caserta M, Bertello C et al. Aldosterone as an independent factor in cerebrovascular damage. Clin Exp Hypertens 2008; 30: 785-797
• 5 Connell JM, MacKenzie SM, Freel EM et al. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008; 29: 133-154
• 6 Tomaschitz A, März W, Pilz S et al. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol 2010; 55: 2171-2180
• 7 Tomaschitz A, Pilz S, Ritz E et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31: 1237-1247
• 8 Tomaschitz A, Pilz S, Ritz E et al. Association of Plasma Aldosterone With Cardiovascular Mortality in Patients With Low Estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis 2011; 57 (03) 403-414
• 9 Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
• 10 Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
• 11 Zannad F, McMurray JJ, Krum H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364 (01) 11-21
• 12 Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318
• 13 Suzuki J, Iwai M, Mogi M et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-921
• 14 Takai S, Jin D, Muramatsu M et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005; 46: 1135-1139
• 15 Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203
• 16 Petrak O, Widimsky Jr J, Zelinka T et al. Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension. Physiol Res 2006; 55: 597-602
• 17 Winkelmann BR, Marz W, Boehm BO et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001; 2: S1-S73
• 18 Trenkel S, Seifarth C, Schobel H et al. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002; 110: 80-85
• 19 Ritz E, Tomaschitz A. Aldosterone, a vasculotoxic agent – novel functions for an old hormone. Nephrol Dial Transplant 2009; 24: 2302-2305
• 20 Gamliel-Lazarovich A, Gantman A, Coleman R et al. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens 2010; 28 (09) 1900-1907
• 21 Jeong Y, Chaupin DF, Matsushita K et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 2009; 106: 3782-3787
• 22 Schafer A, Fraccarollo D, Hildemann S et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003; 89: 1024-1030
• 23 Kobayashi N, Hara K, Tojo A et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-544
• 24 Pu Q, Neves MF, Virdis A et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003; 42: 49-55
• 25 Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810
• 26 Oberleithner H, Riethmuller C, Schillers H et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 2007; 104: 16281-16286
• 27 Caprio M, Newfell BG, la Sala A et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102: 1359-1367
• 28 Tomaschitz A, Pilz S. Aldosterone to renin ratio – a reliable screening tool for primary aldosteronism?. Horm Metab Res 2011; 42: 382-391